Lancet Rheumatology

Article	Citations
Composite endpoints for Sjögren's Syndrome	387
Is it Autumn for colchicine and osteoarthritis?	283
Cardiovascular risk in gout: time for action	233
Thank you to The Lancet Rheumatology's peer reviewers in 2023	217
FDA approval for anifrolumab in patients with lupus	178
Withholding methotrexate after vaccination with ChAdOx1 nCov19 in patients with rheumatoid or psoriatic arthritis in India (MIVAC I and II): results of two, parallel, assessor-masked, randomised contr	144
Pausing drugs and spacing vaccines: an open question	134
Performance of large language models in rheumatology board-like questions: accuracy, quality, and safety	132
The inclusion of Indigenous voices in health research	131
Integrating evidence from lived experience of Aboriginal people and clinical practice guidelines to develop arthritis educational resources: a mixed-methods study	126
Rheumatic cognitive impairment: a new clinical entity?	126
CD19-targeting CAR T-cell therapy in patients with diffuse systemic sclerosis: a case series	118
Immunoglobulin, glucocorticoid, or combined therapy for multisystem inflammatory syndrome in children	102
How should we define disease and outcomes in axial psoriatic arthritis?	102
Brachial plexopathy: an unusual manifestation of Takayasu arteritis	101
Post-COVID condition in patients with inflammatory rheumatic diseases: a prospective cohort study in the Netherlands	99
Women in rheumatology in Africa	93
Research in Brief	84
Toxic epidermal necrosis-like acute cutaneous lupus erythematosus	83
Getting serious about sex and gender	74
Novel COVID-19 therapies: the road ahead for rheumatology	74
1-year results of treatment with rituximab in polymyalgia rheumatica: an extension study of a randomised double-blind placebo-controlled trial	72
Unravelling extracellular matrix biomarkers in systemic sclerosis	68
Brett Thombs: an unconventional journey	66
Research in Brief	65

Monoclonal gammopathy of clinical significance: what the rheumatologist needs to know	64
Research in Brief	62
National differences in vaccine hesitancy: a concern for the external validity of vaccine studies	61
The role of skin ultrasound in systemic sclerosis: looking below the surface to understand disease evolution	61
Cervical spinal gout	57
Correction to Lancet Rheumatol 2020; 2: e557–64	56
Research in Brief	55
Long-awaited action on rare diseases	54
Pandemic to endemic: optimising COVID-19 immunity	53
Can contextual factors improve clarity of the results from clinical trials of low back pain?	49
Composite of Relevant Endpoints for Sjögren's Syndrome (CRESS): development and validation of a novel outcome measure	45
Patient–researcher co-presentation of research results to people living with systemic sclerosis	45
Industry involvement in rheumatology consensus-based recommendations: a systematic review	43
Survivorship of revised and multiply revised knee replacements	41
Research in Brief	41
Changing COVID-19 outcomes in patients with rheumatic disease—are we really getting better at this?	41
Idiopathic inflammatory myopathies: current insights and future frontiers	40
Titilola (Lola) Falasinnu: looking out for the overlooked	39
Research in Brief	39
Gender distribution of rheumatologists across Africa (REACT): a cross-sectional survey study	38
Exploring gender differences, medical history, and treatments used in patients with fibromyalgia in the UK using primary-care data: a retrospective, population-based, cohort study	38
Differential effects of oestrogen on class-switch recombination of B cells dependent on sex chromosome complement: a cross-sectional study	38
Research, pregnancy, and the ethics of parental consent	37
Optimal non-opioid analgesic combinations after total hip arthroplasty	37
Precision medicine in Sjögren's disease	37
Gout prevalence is rising in low-income and middle-income countries: are we ready?	36
The outcomes of children born to mothers with autoimmune rheumatic diseases	36
Associations of improvement in laboratory tests with clinical outcomes in patients with active systemic lupus erythematosus: a multinational longitudinal cohort study	36
Research in Brief	35
Thank you to The Lancet Rheumatology's peer reviewers in 2022	35
Immunogenicity, reactogenicity, and safety of two-dose adjuvanted herpes zoster subunit vaccine in patients with systemic lupus erythematosus in South Korea: a single-centre, randomised, double-blind,	34
Do JAK inhibitors affect immune response to COVID-19 vaccination? Data from the MAJIK-SFR Registry	34
Research in Brief	34
The role of antirheumatics in patients with COVID-19	33
Whole-body MRI for juvenile idiopathic arthritis	33
Reigniting the burnt-out health-care workforce	33
Acceptability of the COVID-19 vaccine among patients with chronic rheumatic diseases and health-care professionals: a cross-sectional study in 19 Arab countries	33
Research in Brief	33
Molecular signature-based decision making in the era of targeted therapies for systemic lupus erythematosus	32
From phenotype to pathophysiology—placing rheumatic diseases in an immunological perspective	31
COVID-19 vaccine-induced T-cell responses in patients with rheumatoid arthritis: preferential induction by ChAdOx1	31
Severe COVID-19 as a virus-independent immunothrombotic process – Authors' reply	31
Long-term effect of tocilizumab in patients with giant cell arteritis: open-label extension phase of the Giant Cell Arteritis Actemra (GiACTA) trial	31
Severe COVID-19 as a virus-independent immunothrombotic process	30
TNF inhibitor use during pregnancy in axial spondyloarthritis: are we asking the right questions?	29
Hormone replacement therapy (conjugated oestrogens plus bazedoxifene) for post-menopausal women with symptomatic hand osteoarthritis: primary report from the HOPE-e randomised, placebo-controlled, fea	29
Real-world evidence for prehospital COVID-19 treatment in systemic autoimmune rheumatic disease	29
Cellular and humoral immunity after the third dose of SARS-CoV-2 vaccine in patients treated with rituximab	29
Temporal trends in severe COVID-19 outcomes in patients with rheumatic disease: a cohort study	28
Patient-led research in rheumatology: the way forward?	28

COVID-19 vaccine perceptions and uptake: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey	28
Effect of denosumab on osteolytic lesion activity after total hip arthroplasty: a single-centre, randomised, double-blind, placebo-controlled, proof of concept trial	28
Research in Brief	28
Vasculitis: the promising road ahead	27
Allogeneic haematopoietic stem-cell transplantation in systemic juvenile idiopathic arthritis	27
Cardiovascular events in patients with gout initiating urate-lowering therapy with or without colchicine for flare prophylaxis: a retrospective new-user cohort study using linked primary care, hospita	27
Dermatology response to the Hyperinflammation and HLH Across Specialty Collaboration consensus guideline – Authors' reply	26
Structural racism is a driver of fragmented care and acute care use among people with rheumatic conditions	26
Susac syndrome: challenges of interpreting treatment data in a rare disease	26
Cenerimod, a sphingosine-1-phosphate receptor modulator, versus placebo in patients with moderate-to-severe systemic lupus erythematosus (CARE): an international, double-blind, randomised, placebo-con	26
Identification of red flags for IgG4-related disease: an international European Reference Network for Rare Connective Tissue Diseases framework	26
Research in Brief	25
COVID-19 vasculitis and novel vasculitis mimics	24
Research in Brief	23
Diffuse alveolar haemorrhage during pregnancy in systemic lupus erythematosus	23
Pathways driving tendinopathy and enthesitis: siblings or distant cousins in musculoskeletal medicine?	23
Molecular imaging for systemic sclerosis-interstitial lung disease	23
Efficacy of guselkumab on axial involvement in patients with active psoriatic arthritis and sacroiliitis: a post-hoc analysis of the phase 3 DISCOVER-1 and DISCOVER-2 studies	22
Benralizumab for eosinophilic granulomatosis with polyangiitis: a retrospective, multicentre, cohort study	22
Patient and public involvement in rheumatology research: embracing the wave of change	21
Diagnosis and investigation of suspected haemophagocytic lymphohistiocytosis in adults: 2023 Hyperinflammation and HLH Across Speciality Collaboration (HiHASC) consensus guideline	21
The influence of safety warnings on the prescribing of JAK inhibitors	21
Tocilizumab and glucocorticoids for giant cell arteritis: the learning curve	21
Towards improving the Global Burden of Disease estimates for low back pain	21
Steroids or intravenous immunoglobulin as first line in MIS-C in LMICs	21
Interosseous tendon inflammation in the hands of patients with clinically suspect arthralgia: analysis of MRI data from a prospective cohort study	20
Three-dimensional, in-vitro approaches for modelling soft-tissue joint diseases	20
Time to talk to adults with rheumatic diseases about herpes zoster vaccination	20
FDA expands JAK inhibitors warning: going beyond the data?	20
Uveitis relapse in Behçet's disease: a more nuanced approach is needed	19
Clinical assessment and management of lumbar spinal stenosis: clinical dilemmas and considerations for surgical referral	19
The impact of treatment with avacopan on health-related quality of life in antineutrophil cytoplasmic antibody-associated vasculitis: a post-hoc analysis of data from the ADVOCATE trial	19
Data-driven subclassification of ANCA-associated vasculitis: model-based clustering of a federated international cohort	19
The effects of age and frailty on the risks of end-stage renal disease, death, and severe infection in older adults with antineutrophil cytoplasmic antibody-associated vasculitis: a retrospective coho	19
Calcium pyrophosphate deposition disease	19
Impact of low disease activity, remission, and complete remission on flares following tapering of corticosteroids and immunosuppressive therapy in patients with systemic lupus erythematous: a multinat	19
Humoral and cellular immunogenicity to a second dose of COVID-19 vaccine BNT162b2 in people receiving methotrexate or targeted immunosuppression: a longitudinal cohort study	18
Bilateral anterior non-necrotising scleritis, anterior uveitis, and unilateral facial nerve palsy in paediatric inflammatory multisystem syndrome temporally associated with COVID-19	18
Tumour necrosis factor inhibitor safety in rheumatoid arthritis-associated interstitial lung disease	17
Safety and efficacy of mirikizumab versus secukinumab and placebo in the treatment of moderate-to-severe plaque psoriasis (OASIS-2): a phase 3, multicentre, randomised, double-blind study	17
Anti-tumour necrosis factor therapy for early-stage Dupuytren's disease (RIDD): a phase 2b, randomised, double-blind, placebo-controlled trial	17
Breakthrough SARS-CoV-2 infections and prediction of moderate-to-severe outcomes during rituximab therapy in patients with rheumatic and musculoskeletal diseases in the UK: a single-centre cohort stud	17
The effect of methotrexate and targeted immunosuppression on humoral and cellular immune responses to the COVID-19 vaccine BNT162b2: a cohort study	16
Beyond very early systemic sclerosis: deciphering pre‑scleroderma and its trajectories to open new avenues for preventive medicine	16
The autoimmune response as a potential target for tolerance induction before the development of rheumatoid arthritis	16
Immunoglobulin, glucocorticoid, or combination therapy for multisystem inflammatory syndrome in children: a propensity-weighted cohort study	16
Flare of rheumatoid arthritis after COVID-19 vaccination	15
Clinical meaningfulness of a British Isles Lupus Assessment Group-based Composite Lupus Assessment response in terms of patient-reported outcomes in moderate to severe systemic lupus erythematosus: a	15
Naltrexone 6 mg once daily versus placebo in women with fibromyalgia: a randomised, double-blind, placebo-controlled trial	15
Burden of rheumatoid arthritis and forecasted prevalence to 2050	15
Early infection risk in patients with systemic lupus erythematosus treated with rituximab or belimumab from the British Isles Lupus Assessment Group Biologics Register (BILAG-BR): a prospective longit	14
The influence of sex hormones on musculoskeletal pain and osteoarthritis	14
Progression of patients with Raynaud's phenomenon to systemic sclerosis: a five-year analysis of the European Scleroderma Trial and Research group multicentre, longitudinal registry study for Very Ear	14
Targeting synovial fibroblast proliferation in rheumatoid arthritis (TRAFIC): an open-label, dose-finding, phase 1b trial	14
Challenges of a stratified care approach to musculoskeletal pain	14
Mortality and adverse events of special interest with intravenous belimumab for adults with active, autoantibody-positive systemic lupus erythematosus (BASE): a multicentre, double-blind, randomised,	14
Detection of decline in pulmonary function in patients with systemic sclerosis-associated interstitial lung disease using home monitoring in the Netherlands (DecreaSSc): a prospective, observational s	13
Palliative care in patients with rheumatic diseases	13
Correction to Lancet Rheumatol 2023; 5: e274–83	13
Combinations of immunomodulatory agents for prevention of uveitis relapse in patients with severe Behçet's disease already on corticosteroid therapy: a randomised, open-label, head-to-head trial	13
Definition and validation of serum biomarkers for optimal differentiation of hyperferritinaemic cytokine storm conditions in children: a retrospective cohort study	13
Correction to Lancet Rheumatol 2022; 4: e853–63	12
Global, regional, and national burden of gout, 1990–2020, and projections to 2050: a systematic analysis of the Global Burden of Disease Study 2021	12
Treatment tapering and stopping in patients with rheumatoid arthritis in stable remission (RETRO): a multicentre, randomised, controlled, open-label, phase 3 trial	12
No perfect therapy for the imperfect COVID-19 cytokine storm	12
Understanding the multiple dimensions of ageing: 5Ms for the rheumatologist	12
Correction to Lancet Rheumatol 2022; 4: e177–87	12
A disseminated gonococcal infection with spinal locations	12
Tolerance of COVID-19 vaccination in patients with systemic lupus erythematosus: the international VACOLUP study	12
Mortality and immune-related adverse events after immune checkpoint inhibitor initiation for cancer among patients with pre-existing rheumatoid arthritis: a retrospective, comparative, cohort study	12
The projected burden of arthritis among adults and children in Australia to the year 2040: a population-level forecasting study	12
Patients with gout: an under-recognised group at high risk of COVID-19	12
Sex-related differences in patient characteristics, and efficacy and safety of advanced therapies in randomised clinical trials in psoriatic arthritis: a systematic literature review and meta-analysis	12
Rhombencephalitis with longitudinal extensive transverse myelitis in lupus: an overlap syndrome?	11
Arthritis mutilans in juvenile idiopathic arthritis	11
Game-changing therapies for people with giant cell arteritis?	11
Composite endpoints for Sjögren's Syndrome	11
Research in Brief	11
Differentiating biologics to prevent psoriatic arthritis in patients with psoriasis	11
Correction to Lancet Rheumatol 2020; 2: e666–76	11

Treating subclinical arthritis: prevention or overtreatment?	11
Central sensitisation: causes, therapies, and terminology – Authors' reply	11
Research in Brief	10
Surgical microdiscectomy versus transforaminal epidural steroid injection in patients with sciatica due to lumbar disc herniation	10
Stop ticking boxes: it just doesn't work	10
Research in Brief	10
Potential for false decline of anti-SARS-CoV-2 spike antibody titers after COVID-19 vaccination	10
Michael Barrett: navigating hostile terrain	10
Allogeneic mesenchymal stromal cell transplantation for systemic sclerosis	10
New insights into the pathogenesis of giant cell arteritis: are they relevant for precision medicine?	10
Interleukin-5 inhibition in eosinophilic granulomatosis with polyangiitis: time for another approach?	10
Quantification of 68Ga-FAPI-04 in systemic sclerosis-associated interstitial lung disease – Authors' reply	10
Welcome new evidence on self-management of back pain	10
Tuning up UK clinical trials	10
Progressive unilateral facial asymmetry in a young girl	10
Treatment for giant cell arteritis with 8 weeks of prednisone in combination with tocilizumab: a single-arm, open-label, proof-of-concept study	10
How can trial designs better serve the needs of children and young people with juvenile idiopathic arthritis?	10
Sex bias in IgG4-related disease: from clinical phenotype to mechanisms	10
Juvenile systemic lupus erythematosus presenting as retinal vasculitis	9
Early-stage Dupuytren's disease treatment; a promising next step?	9
Immunogenicity of third dose COVID-19 vaccine strategies in patients who are immunocompromised with suboptimal immunity following two doses (OCTAVE-DUO): an open-label, multicentre, randomised, contro	9
Preventive medicine in rheumatology: COVID-19 and its lessons for better health outcomes	9
Riociguat in systemic sclerosis: challenges in crossing the bridge from bench to bedside	9
Immunomodulatory and immunosuppressive medication modification among patients with rheumatic diseases at the time of COVID-19 vaccination	9
Adolescent sarcoidosis mimicking malignant lymphoma	9
Cellular responses to SARS-CoV-2 vaccination after B-cell depletion: conflicting results from studies – Authors' reply	9
Global, regional, and national burden of low back pain, 1990–2020, its attributable risk factors, and projections to 2050: a systematic analysis of the Global Burden of Disease Study 2021	9
Leflunomide in the treatment of psoriatic arthritis	9
Evaluation of supported self-management in gout (GoutSMART): a randomised controlled feasibility trial	9
Research in Brief	9
Role of plasma exchange in ANCA-associated vasculitis	9
Identification of distinct subgroups of Sjögren's disease by cluster analysis based on clinical and biological manifestations: data from the cross-sectional Paris-Saclay and the prospective ASSESS coh	9
Risks and benefits of tocilizumab monotherapy in giant cell arteritis	8
Targeting mTOR in sarcoid granulomas: where the rubber meets the road	8
Pausing drugs and spacing vaccines: an open question – Authors' reply	8
Association of economic insecurities with patient-reported outcomes in systemic lupus erythematosus	8
Cellular responses to SARS-CoV-2 vaccination after B-cell depletion: conflicting results from studies	8
Expanding role of biomarkers in characterising hyperinflammatory syndromes – Authors' reply	8
Thank you to our contributors and peer reviewers in 2023	7
Targeting GM-CSF in rheumatological conditions: risk of PAP – Authors' reply	7
Painful scalp nodules in SAPHO syndrome	7
Immunocompromised patients in the USA and UK should receive third dose of COVID-19 vaccine	7
SARS-CoV-2 outbreak in immune-mediated inflammatory diseases: the Euro-COVIMID multicentre cross-sectional study	7
Ngozi Chiejina: perseverance in the face of adversity	7
The unsustainable bubble of disease-modifying antirheumatic drugs in rheumatology	7
Assessment of treatment efficacy in polymyalgia rheumatica	7
Systemic lupus erythematosus: managing cardiovascular risk factors	7
JAK inhibitors—Friend or Foe?	7
Artificial intelligence and high-dimensional technologies in the theragnosis of systemic lupus erythematosus	7
Systemic sclerosis and COVID-19 vaccines: a SPIN Cohort study	7
Characterisation of a high-risk profile for maternal thrombotic and severe haemorrhagic complications in pregnant women with antiphospholipid syndrome in France (GR2): a multicentre, prospective, obse	7
Biosimilars and the era of interchangeability	7
The Florida Scoring System for stratifying children with suspected Sjögren's disease: a cross-sectional machine learning study	7
Disease stratification in giant cell arteritis to reduce relapses and prevent long-term vascular damage	7
Assessing glucocorticoid toxicity: are the measures sensitive enough?	7
Quantification of 68Ga-FAPI-04 in systemic sclerosis-associated interstitial lung disease	7
COVID-19: angiotensin II in development of lung immunothrombosis and vasculitis mimics	7
A molecular signature as a guidance for glucocorticoid: are we there yet?	7
Latika Gupta: a thinker and a doer for myositis research	6
Effect of the COVID-19 pandemic on patients with systemic rheumatic diseases	6
Safety and efficacy of tofacitinib up to 48 months in patients with active psoriatic arthritis: final analysis of the OPAL Balance long-term extension study	6
Review or perish, regardless of your attempts to publish	6
Anti-citrullinated protein antibodies dominate the association of long-term outcomes and anti-modified protein antibodies in rheumatoid arthritis	6
Investigating sex differences in T regulatory cells from cisgender and transgender healthy individuals and patients with autoimmune inflammatory disease: a cross-sectional study	6
Bilateral linear scleroderma with transition into progressive facial hemiatrophy	6
Non-opioid analgesic combinations following total hip arthroplasty (RECIPE): a randomised, placebo-controlled, blinded, multicentre trial	6
Protecting patients with SLE against herpes zoster: time for early proactive vaccine counselling	6
Therapeutic drug monitoring countering the effect of anti-infliximab antibodies	6
Predicting COVID-19 vaccination response in populations who are immunosuppressed	6
Variability in counselling for adrenal insufficiency in COVID-19 and beyond: a survey of rheumatology practice	6
Identifying key health system components associated with improved outcomes to inform the re-configuration of services for adults with rare autoimmune rheumatic diseases: a mixed-methods study	6
Immunity after COVID-19 vaccinations in immunocompromised patients with psoriasis	6
The concept of difficult-to-treat disease in rheumatology: where next?	6
Evaluation of SARS-CoV-2 IgG antibody reactivity in patients with systemic lupus erythematosus: analysis of a multi-racial and multi-ethnic cohort	6
Genetic IL-6R variants and therapeutic inhibition of IL-6 receptor signalling in COVID-19	6
Proof-of-concept studies in axial spondyloarthritis: there are no shortcuts	5
Association of sustained lupus low disease activity state with improved outcomes in systemic lupus erythematosus: a multinational prospective cohort study	5
Patient-reported outcomes with anifrolumab in patients with systemic lupus erythematosus	5
2022: a banner year for systemic lupus erythematosus?	5
Challenges of designing and conducting cohort studies and clinical trials in populations of pregnant people	5
Trends in opioid use for autoimmune rheumatic diseases	5
Pregnancy outcomes in women with primary Sjögren's syndrome: an analysis of data from the multicentre, prospective, GR2 study	5
Research in Brief	5
Effects of tapering conventional synthetic disease-modifying antirheumatic drugs to drug-free remission versus stable treatment in rheumatoid arthritis (ARCTIC REWIND): 3-year results from an open-lab	5
Outcomes after anti-tumour necrosis factor originator to biosimilar switching in children and young people with juvenile idiopathic arthritis in the UK: a national cohort study	5
Navigating the complexities of pregnancy in rheumatic disease	5
Tapering of disease-modifying antirheumatic drugs: an overview for daily practice	5
COVID-19 vaccine data provide reassurance	5
Gender differences in the incidence of systemic lupus erythematosus in Norway: a population-based cohort study	5
Moderators of the effect of therapeutic exercise for knee and hip osteoarthritis: a systematic review and individual participant data meta-analysis	4
Predictors of pregnancy outcomes in SLE	4
Role of neutrophil interleukin-23 in spondyloarthropathy spectrum disorders	4
Pain in the joints and beyond; the challenge of rheumatoid arthritis	4
Predictors of pregnancy outcomes in SLE	4
Effect of a 2-week interruption in methotrexate treatment on COVID-19 vaccine response in people with immune-mediated inflammatory diseases (VROOM study): a randomised, open label, superiority trial	4